background: infections due to pseudomonas aeruginosa are among the leading causes of morbidity and mortality in patients who suffer from impaired immune responses and chronic diseases such as cystic fibrosis. at present, aggressive antibiotic therapy is the only choice for management of p. aeruginosa infections, but emergence of highly resistant strains necessitated the development of novel alt...

background: antibiotic resistance and the need for long-term treatments especially for chronic infections necessitate the developmentof a vaccine against pseudomonas aeruginosa infection.objectives: in this study, recombinant exotoxin a (domains i and ii), (exoa i-ii) protein was expressed, purifid and its immunologicalcharacteristics were evaluated in a mouse model.materials and methods: the g...

Background: DNA immunization is an appropriate method to produce an immunological response. Pseudomonas aeruginosa produces exotoxin A which is highly cytotoxic for eukaryotic cells. Since domains II (translocation domain) and 1b of the toxin have antigenic qualities, so they could be  useful candidates to protect against pseudomonas infections. Objectives: To evaluate if recombinant plasmid co...

pseudomonas aeruginosa as an opportunistic pathogen produces several virulence factors. the most important of these factors are exotoxin a and type iii secretion system (t3ss). the aim of this study was to determine the frequency of toxa, exou and exos genes among clinical isolates of p. aeruginosa. in this cross-sectional study from september 2011 to february 2012, 156 p. aeruginosa isolates w...

Seventy-five consecutive clinical Pseudomonas aeruginosa isolates were tested for in vitro exotoxin production. Exotoxin was demonstrated in culture filtrates biologically, by its ability to produce characteristic dermonecrotic lesions in guinea pigs, and seriologically, by counterimmunoelectrophoresis (CIE) with rabbit antiserum elicited with purified exotoxin. By these two methods, exotoxin w...